Kannan SK, Turner TJ, Heidarian M, Mix MR, Kim CY, Fain C, Shahi SK, Escue EA, Ezeilo I, Griffith TS, Mangalam AK, Harty JT, Badovinac VP (2026 Jul 10). Whole-body irradiation causes long-term impairments in the maintenance and function of naïve CD4 T cells specific for self- and non-self-antigens. Journal of immunology (Baltimore, Md. : 1950), 215(7). PubMed ID: 42441427. Read the article.
Kim CY, Ding H, Mirabadi N, Luo S, Scherler K, Walters KA, O'Keefe G, Griffith TS, Brakenridge SC (2026 Jun 7). Distinct immune trajectories after severe trauma identify a Th17-biased immunophenotype in chronic critical illness. Journal of immunology (Baltimore, Md. : 1950), 215(6). PubMed ID: 42343164. Read the article.
Caldwell CC, Maile R, Mazer MB, McGonagill PW, Bergmann CB, Gould RW, Rao M, Hernández-Ríos M, Ungaro RF, Loftus TJ, Efron PA, Remy KE, Brakenridge SC, Badovinac VP, Griffith TS, Hotchkiss RS, Moldawer LL (2026 Mar 1). Quantifying Nuance Within Sepsis-Associated Immune Suppression Toward Diagnostic Certainty. Shock (Augusta, Ga.), 65(3), 555-559. PubMed ID: 41166166. Read the article.
Funk GA, Xie J, Kucaba TA, Griffith TS, Ferguson DM, Kim H (2026 Jan 9). Toll-Like Receptor 7/8 Antagonist Promotes Interleukin-10-Mediated Anti-inflammatory Therapy. ACS pharmacology & translational science, 9(1), 114-125. PubMed ID: 41536275. Read the article.
Bhatnagar S, Revuri V, Merali C, Wang B, Schultz JR, Larson P, Yu D, Prabha S, Griffith TS, Ferguson D, Merali S, Panyam J (2026 Jan 1). A Novel Imidazoquinoline With TLR 7/8, STING, and Inflammasome Activity Demonstrates Antitumor Efficacy in Mouse Melanoma and Neu-Driven Mammary Adenocarcinoma. Journal of immunotherapy (Hagerstown, Md. : 1997), 49(1), 1-14. PubMed ID: 40765175. Read the article.
Mondal J, Prabha S, Griffith TS, Ferguson D, Panyam J (2025 Nov 6). Enhancing Cancer Therapy with TLR7/8 Agonists: Applications in Vaccines and Combination Treatments. Cancers, 17(21). PubMed ID: 41228373. Read the article.
Stegnjaić G, Mićanović D, Saksida T, Despotović S, Griffith TS, Badovinac VP, Miljković Đ, Stanisavljević S (2025). Sepsis prevents the development of experimental type 1 diabetes. Frontiers in immunology, 16, 1658960. PubMed ID: 41142792. doi: https://doi.org/10.3389/fimmu.2025.1658960.
Heidarian M, Kannan SK, Swanson W, Griffith TS, Harty JT, Badovinac VP (2025 Sep 23). Delineating the short- and long-term impact of ionizing radiation on antigen-inexperienced CD8+ T cell subsets. JCI insight, 10(18). PubMed ID: 40762983. Read the article.
Mix MR, Kreitlow BL, Berton RR, Xu J, Fain CE, van de Wall S, Pewe LL, Hancox LS, Hassert MA, Kannan SK, Arumugam SA, Sievers CM, Buchanan GF, Griffith TS, Badovinac VP, Harty JT (2025 Jul). Physiological microbial exposure normalizes memory T cell surveillance of the brain and modifies host seizure outcomes. Nature immunology, 26(7), 1087-1098. PubMed ID: 40514419. Read the article.
Walton AH, Mazer MB, Remy KE, Osborne DF, Davitt EB, Griffith TS, Gould RW, Badovinac VP, Brakenridge SC, Drewry AM, Ungaro RF, Rocha IL, Loftus TJ, Efron PA, Moldawer LL, Caldwell CC, Hotchkiss RS (2025 Apr 18). Determining potential immunomodulatory drug efficacy in sepsis using ELISpot. Scientific reports, 15(1), 13464. PubMed ID: 40251188. Read the article.
